Search Results

There are 20241 results for: content related to: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials

  1. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  2. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  3. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  4. Biologics for rheumatoid arthritis: an overview of Cochrane reviews

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, Robin Christensen, George A Wells, Maria E Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu and Peter Tugwell

    Published Online : 7 OCT 2009, DOI: 10.1002/14651858.CD007848.pub2

  5. You have free access to this content
    Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

    Arthritis & Rheumatism

    Volume 48, Issue 1, January 2003, Pages: 35–45, Michael E. Weinblatt, Edward C. Keystone, Daniel E. Furst, Larry W. Moreland, Michael H. Weisman, Charles A. Birbara, Leah A. Teoh, Steven A. Fischkoff and Elliot K. Chartash

    Version of Record online : 10 JAN 2003, DOI: 10.1002/art.10697

  6. You have full text access to this OnlineOpen article
    Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

    Arthritis & Rheumatism

    Volume 65, Issue 1, January 2013, Pages: 28–38, Michael E. Weinblatt, Michael Schiff, Robert Valente, Désirée van der Heijde, Gustavo Citera, Cathy Zhao, Michael Maldonado and Roy Fleischmann

    Version of Record online : 27 DEC 2012, DOI: 10.1002/art.37711

  7. You have free access to this content
    Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

    Arthritis & Rheumatism

    Volume 56, Issue 2, February 2007, Pages: 476–488, Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok and Eric H. Sasso

    Version of Record online : 30 JAN 2007, DOI: 10.1002/art.22379

  8. Adalimumab for treating rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Federico Navarro-Sarabia, Rafael Ariza-Ariza, Blanca Hernandez-Cruz and Isidro Villanueva

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD005113.pub2

  9. You have free access to this content
    Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

    Arthritis & Rheumatism

    Volume 50, Issue 5, May 2004, Pages: 1400–1411, Edward C. Keystone, Arthur F. Kavanaugh, John T. Sharp, Hyman Tannenbaum, Ye Hua, Leah S. Teoh, Steven A. Fischkoff and Elliot K. Chartash

    Version of Record online : 6 MAY 2004, DOI: 10.1002/art.20217

  10. Adalimumab (Humira)

    Handbook of Therapeutic Antibodies

    Hartmut Kupper, Jochen Salfeld, Daniel Tracey, Joachim R. Kalden, Pages: 696–732, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch27

  11. You have free access to this content
    Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

    Arthritis & Rheumatism

    Volume 64, Issue 12, December 2012, Pages: 3850–3855, Charlotte L. Krieckaert, Anna Jamnitski, Michael T. Nurmohamed, Piet J. Kostense, Maarten Boers and Gertjan Wolbink

    Version of Record online : 28 NOV 2012, DOI: 10.1002/art.34680

  12. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate

    APLAR Journal of Rheumatology

    Volume 10, Issue 1, April 2007, Pages: 9–16, Ho-Youn KIM, Soo-Kon LEE, Yeong Wook SONG, Dae-Hyun YOO, Eun-Mi KOH, Bin YOO and Allison LUO

    Version of Record online : 8 MAR 2007, DOI: 10.1111/j.1479-8077.2007.00248.x

  13. You have free access to this content
    Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 9, November 2014, Pages: 1044–1055, C. Ma, V. Huang, D. K. Fedorak, K. I. Kroeker, L. A. Dieleman, B. P. Halloran and R. N. Fedorak

    Version of Record online : 3 SEP 2014, DOI: 10.1111/apt.12940

  14. You have free access to this content
    The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

    Arthritis & Rheumatism

    Volume 54, Issue 1, January 2006, Pages: 26–37, Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley B. Cohen, Karel Pavelka, Ronald van Vollenhoven, John Sharp, John L. Perez and George T. Spencer-Green

    Version of Record online : 29 DEC 2005, DOI: 10.1002/art.21519

  15. You have free access to this content
    Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

    Arthritis & Rheumatism

    Volume 64, Issue 3, March 2012, Pages: 617–629, Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese, Eun Bong Lee, Keith S. Kanik, Seth Sadis, Carol A. Connell, David Gruben, Sriram Krishnaswami, Gene Wallenstein, Bethanie E. Wilkinson and Samuel H. Zwillich

    Version of Record online : 28 FEB 2012, DOI: 10.1002/art.33383

  16. You have free access to this content
    Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial

    Arthritis & Rheumatism

    Volume 52, Issue 10, October 2005, Pages: 3279–3289, Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Eric M. Ruderman, Serge D. Steinfeld, Ernest H.S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok and Mark A. Weinberg

    Version of Record online : 30 SEP 2005, DOI: 10.1002/art.21306

  17. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell and George A Wells

    Published Online : 13 MAY 2016, DOI: 10.1002/14651858.CD012183

  18. You have full text access to this OnlineOpen article
    A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis

    International Journal of Rheumatic Diseases

    Volume 19, Issue 11, November 2016, Pages: 1157–1168, Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia, Gaurav Rathi, Patnala Ashok Kumar, Reena Sharma, Uma Kumar, Liyakat A. Gauri, Praveen Jadhav, Girishchandra Bartakke, Vikram Haridas, Dinesh Jain and Sanjeev K. Mendiratta

    Version of Record online : 14 JUL 2015, DOI: 10.1111/1756-185X.12711

  19. You have free access to this content
    Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 12, June 2010, Pages: 1296–1309, R. PANACCIONE, J.-F. COLOMBEL, W. J. SANDBORN, P. RUTGEERTS, G. R. D’HAENS, A. M. ROBINSON, J. CHAO, P. M. MULANI and P. F. POLLACK

    Version of Record online : 18 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04304.x

  20. You have free access to this content
    Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

    The Journal of Dermatology

    Volume 37, Issue 4, April 2010, Pages: 299–310, Akihiko ASAHINA, Hidemi NAKAGAWA, Takafumi ETOH, Mamitaro OHTSUKI and THE ADALIMUMAB M04-688 STUDY GROUP

    Version of Record online : 26 FEB 2010, DOI: 10.1111/j.1346-8138.2009.00748.x